Rapid Fire 4

Moderator

Bora Lim, UT MD Anderson Cancer Center, Houston, TX

Presentation numberRF4-01

Central Nervous System Outcomes from the Phase III PATINA Trial (AFT-38)

Otto Metzger, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Presentation numberRF4-02

Efficacy Analysis of the Randomized Phase III DETECT V trial: Treatment De-escalation by Omission of Chemotherapy and the Effect of Adding Ribociclib in HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer

Wolfgang Janni, University Hospital Ulm, Ulm, Germany

Presentation numberRF4-03

Evaluation of a whole-exome sequencing tumor-informed circulating tumor DNA MRD assay in patients with early triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAC) with or without atezolizumab: A prospective sub study of the NSABP-B59/GBG-96-GeparDouze Trial

Marija Balic, NSABP Foundation, Inc.; UPMC Hillman Cancer Center; University of Pittsburgh School of Medicine, Pittsburgh, PA

Presentation numberRF4-04

Mechanisms of resistance to capivasertib in combination with CDK4/6 inhibitor (CDK4/6i) plus fulvestrant in patients with hormone receptor-positive/HER2-negative (HR+/HER2−) advanced breast cancer (ABC): exploratory analysis from the Phase 1b CAPItello-292 study

Dhivya Raja Sudhan, AstraZeneca, Gaithersburg, MD

Presentation numberRF4-05

PIK3R1 (p85α) alterations define a targetable subset of breast cancer with broad sensitivity to PI3K and AKT inhibitors

Shalinda Fernando, NYU Langone, New York, NY

Presentation numberRF4-06

Fdg-pet to assess therapeutic response in patients with bone-dominant metastatic breast cancer, feature: ecog-acrin ea1183

Jennifer Marie Specht, University of Washington/Fred Hutch Cancer Center, Seattle, WA

Presentation numberRF4-07

Genomic characteristics of de novo HER2-positive metastatic breast cancer

Shu Yazaki, Memorial Sloan Kettering Cancer Center, New York, NY